Safety and efficacy of Lavipan? (Lactococcus?lactis B/00039, Carnobacterium?divergens KKP 2012p, Lactobacillus?casei B/00080, Lactobacillus?plantarum B/00081 and Saccharomyces?cerevisiae KKP 2059p) for weaned piglets, chickens for fattening and turkeys for fattening

摘要

Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Lavipan? (Lactococcus lactis B/00039, Carnobacterium divergens KKP 2012p, Lactobacillus casei B/00080, Lactobacillus plantarum B/00081 and Saccharomyces cerevisiae KKP 2059p) when used as a zootechnical additive for weaned piglets, chickens and turkeys for fattening at the minimum dose of 5 x 108 colony forming unit (CFU) lactic acid bacteria (LAB)/kg feed and 5 x 106 CFU S. cerevisiae/kg feed. The species Lc. lactis, C. divergens, Lb. casei, Lb. plantarum and S. cerevisiae are considered by EFSA to be suitable for the qualified presumption of safety (QPS) approach to safety assessment and not to require specific demonstration of safety other than demonstrating the absence of resistance to antibiotics of human and veterinary significance. The identity of all strains has been established and no antibiotic resistance of concern detected. Following the QPS approach to safety assessment, these strains are presumed safe for the target species, consumers of products from animals fed the additive and the environment. Lavipan? is not toxic by inhalation or a dermal/ocular irritant, but should be considered as a potential respiratory sensitiser. In the absence of data, no conclusion can be drawn on the skin sensitisation potential. Lavipan? has the potential to improve the performance of chickens for fattening when supplemented at the recommended dose of 5 x 108 CFU LAB/kg feed and 5 x 106 CFU S. cerevisiae/kg feed. No conclusions can be drawn on the efficacy of Lavipan? when added to feed for weaned piglets or turkeys for fattening. Lavipan? is compatible with diclazuril, salinomycin sodium, decoquinate, maduramicin and narasin+nicarbazin.